Drugs / B lymphocytes adjuvant
last change Aug 2024 re-read 2 minutes ago

B lymphocytes adjuvant

Developed for
digestive system cancer
Investigated by
Peking University

Trials 1 · a red edge is where a trial was stopped

202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05730361 Feb 2023 → May 2024 digestive system cancer Peking University Unknown No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as B lymphocytes adjuvant ClinicalTrials.gov intervention name — accepted as the source's own label NCT05730361